Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Qyuns Therapeutics Co., Ltd. Class H ( (HK:2509) ).
Qyuns Therapeutics Co., Ltd. has successfully completed the placement of 5,000,000 new H Shares under a general mandate, with TruMed Health Innovation Fund LP acquiring the shares at HK$20.0 each. This transaction represents approximately 2.20% of the company’s issued shares post-placement, enhancing its capital base and potentially strengthening its market position. TruMed, a Cayman Islands-based investment fund, is a significant player in healthcare equities, and its involvement may signal confidence in Qyuns Therapeutics’ future prospects.
The most recent analyst rating on (HK:2509) stock is a Hold with a HK$26.00 price target. To see the full list of analyst forecasts on Qyuns Therapeutics Co., Ltd. Class H stock, see the HK:2509 Stock Forecast page.
More about Qyuns Therapeutics Co., Ltd. Class H
Qyuns Therapeutics Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating within the healthcare industry. The company focuses on the development and distribution of therapeutic solutions and is listed on the Hong Kong Stock Exchange under the stock code 2509.
Average Trading Volume: 491,350
Technical Sentiment Signal: Buy
For a thorough assessment of 2509 stock, go to TipRanks’ Stock Analysis page.